Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKG-200
- Development stage
- Preclinical
- Lead developer
- Akagera Medicines
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
AKG-200 is a preclinical mRNA-based prophylactic vaccine being developed by Akagera Medicines for the prevention of tuberculosis (*Mycobacterium tuberculosis*). As part of Akagera's mRNA vaccine platform, AKG-200 is designed to deliver genetic instructions to host cells to produce specific mycobacterial antigens, thereby eliciting a protective immune response against TB infection. The program is currently in the preclinical stage, aiming to provide a modern alternative or supplement to existing tuberculosis vaccines like BCG.
- Other names
- ligand-directed mRNA-LNP TB vaccineAkagera TB vaccine
Beyond the preview
Go deeper on AKG-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKG-200.